Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 351

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 351
---
 short -swingprofits recapture rules, and certain governance requirements such as independent director oversight of the nomination of directors and executive compensation. In addition, NLS is not required to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies registered under the Exchange Act. Starting the last quarter of 2023, NLS began to adjust its workforce, primarily comprised of consultants. On March20, 2024, NLS announced that it had secured Exclusive Global License for Next -GenerationNon -SulfonamideDual Orexin Agonist Platform. On March22, 2024, NLS announced the closing of $1.75 Million Registered Direct Offering. After the consummation of the Merger, NLS’s principal executive office will remain at The Circle6, 8058 Zurich, Switzerland, Tel: +41.44.512.2150. Business Overview NLS is a clinical -stagebiopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex CNS disorders with unmet medical needs. NLS’s lead compound mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary extended -release, or ER formulation, is being developed for the treatment of narcolepsy (lead indication) and ADHD (follow -onindication). NLS believes that this dual mechanism of action will also enable mazindol ER to provide potential therapeutic benefit in other rare and complex CNS disorders. CNS disorders are a diverse group of conditions that include neurological, psychiatric, and substance use disorders. According to the World Health Organization and based on data from the Global Burden of Disease Report, CNS disorders result in a socio -economicburden of more than $317billion annually in the United States alone. Additionally, CNS disorders were expected to account for approximately 15% of the global disease burden in 2020, the largest of any disease area. However, treatment options for these conditions are often limited, inadequate or nonexistent, and the development of new CNS treatments generally trails behind 165 other therapeutic areas. NLS is pursuing the development of the next generation of CNS therapies with high medical impact to address this critical and growing unmet need. NLS’s dual development strategy is designed to optimize the outcome of its clinical programs by developing new chemical entities from known molecules with strong scientific rationale, and also by re -definingpreviously approved molecules with well -established